Alphaviral Vector Cell Lines for Stable Protein Expression

Resolve Bottlenecks,
Find Innovative Solutions
Generate Solutions

Solution Overview

Problem

Current alphaviral vector systems for expressing genes in mammalian cells face challenges such as cytopathicity, mutation accumulation, and variable expression levels, limiting their ability to produce recombinant proteins stably and at high levels.

Innovation Solution

A polynucleotide comprising a minimal albumin promoter with a DNA sequence complementary to an alphavirus replicon, integrated into the cell genome, and flanked by site-specific recombinase recognition sequences, allowing for regulable expression and easy exchange of genes using recombinase-mediated cassette exchange.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Productivity

If alphaviral vectors are used for gene expression in mammalian cells, then high-level protein expression is achieved, but cytopathicity occurs limiting long-lasting expression

Engineering Contradiction:
Improveprotein expression levelVSAvoidlong-lasting expression stability
Core Design Contradiction:
ProductivityVSReliability

Solution Approach 1:

The patent extracts and removes the structural genes (capsid, envelope, 6K) from the alphavirus replicon, retaining only the non-structural replicase genes and essential replication elements. This creates a replicon-based expression system that maintains high protein expression while eliminating cytopathic effects caused by viral structural proteins, enabling long-lasting stable expression in mammalian cells

Inventive Principle:
Principle #2Taking out (Extraction)

Solution Approach 2:

The patent uses a DNA sequence complementary to the alphavirus replicon as an intermediary element that can be integrated into the host cell genome. This complementary DNA sequence serves as a template for generating the RNA replicon in trans, mediating between the stable integrated DNA and the active RNA replication machinery, thereby ensuring both genomic stability and sustained high-level expression

Inventive Principle:
Principle #24Intermediary (Mediator)

2Reliability

If non-cytopathic alphavirus mutants are used, then long-lasting expression is achieved, but expression levels drop to about 4% of original SIN vector

Engineering Contradiction:
Improvelong-lasting expressionVSAvoidexpression level
Core Design Contradiction:
ReliabilityVSProductivity

Solution Approach 1:

The patent introduces specific point mutations in the nsp2 protein (P718T and R649H) that alter the replicase function to reduce cytopathicity while maintaining replication efficiency. These parameter changes in the replicase enzyme allow the system to achieve both long-lasting expression and high expression levels, overcoming the trade-off observed in previous mutants

Inventive Principle:
Principle #35Parameter changes

3Reliability

If constitutive expression from integrated replicon is used, then stable cell lines are generated, but mutation accumulation occurs due to constant viral replicase copying

Engineering Contradiction:
Improvestable cell line generationVSAvoidgene sequence fidelity
Core Design Contradiction:
ReliabilityVSStability of the object's composition

Solution Approach 1:

The patent implements inducible expression systems using tetracycline-responsive elements (TRE) that allow dynamic control of replicon activity. The viral replicase is expressed only when induced by tetracycline or doxycycline, rather than constitutively. This dynamic control prevents mutation accumulation during cell passage while maintaining the ability to generate stable cell lines with high expression when needed

Inventive Principle:
Principle #15Dynamics

4Reliability

If antibiotic selection is used to maintain replicon expression, then stable cell lines are obtained, but cells adapt requiring smaller replicon amounts decreasing expression levels

Engineering Contradiction:
Improvestable cell line maintenanceVSAvoidexpression level
Core Design Contradiction:
ReliabilityVSProductivity

Solution Approach 1:

The patent employs inducible expression systems with tetracycline-responsive elements that provide feedback control of replicon activity. Instead of relying on antibiotic selection that leads to adaptive downregulation, the system allows researchers to induce high-level expression only when needed, maintaining full replicon functionality and expression capacity without selective pressure-driven adaptation

Inventive Principle:
Principle #23Feedback

Data Source

PatentEP3000890B1Alphaviral vectors and cell lines for producing recombinant proteins
Publication Date: 2019.08.14 3P BIOPHARM
  • EP3000890B1 patent drawingFigure 1~2
  • EP3000890B1 patent drawingFigure 3A~3B
  • EP3000890B1 patent drawingFigure 3C~3D

AI summary

The present invention relates to polynucleotides and alphaviral vectors for the expression of genes of interest in mammalian cells. Additionally, the invention relates to cells which comprise said polynucleotides and alphaviral vectors and are capable of stably expressing one or more genes of interest. The invention also relates to methods for obtaining said cells, to methods for expressing a gene of interest in said cells, and to methods for replacing the gene of interest stably expressed by said cells with another gene of interest.